Clinical Trials Browser

Phase 2/3 × dinutuximab × Clear all

NCT03098030 2020-12-09

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

Phase 2/3 Completed

483 enrolled 19 charts

Small Cell Lung Carcinoma